BerGenBio ASA (BGBIO.OL)

NOK 1.76

(3.9%)

Operating Expenses Summary of BerGenBio ASA

BerGenBio ASA's latest annual operating expenses in 2023 was 192.17 Million NOK , down -37.2% from previous year.
BerGenBio ASA's latest quarterly operating expenses in 2024 Q2 was 51.76 Million NOK , up 118.03% from previous quarter.
BerGenBio ASA reported a annual operating expenses of 306.02 Million NOK in annual operating expenses 2022, down -2.92% from previous year.
BerGenBio ASA reported a annual operating expenses of 315.23 Million NOK in annual operating expenses 2021, up 20.46% from previous year.
BerGenBio ASA reported a quarterly operating expenses of 51.76 Million NOK for 2024 Q2, up 118.03% from previous quarter.
BerGenBio ASA reported a quarterly operating expenses of 28.09 Million NOK for 2023 Q3, down -41.19% from previous quarter.

Annual Operating Expenses Chart of BerGenBio ASA (2023 - 2014)

Historical Annual Operating Expenses of BerGenBio ASA (2023 - 2014)

Year	Operating Expenses	Operating Expenses Growth
2023	192.17 Million NOK	-37.2%
2022	306.02 Million NOK	-2.92%
2021	315.23 Million NOK	20.46%
2020	261.69 Million NOK	22.7%
2019	213.27 Million NOK	8.33%
2018	196.87 Million NOK	7.17%
2017	183.7 Million NOK	39.63%
2016	131.57 Million NOK	80.42%
2015	72.92 Million NOK	22.72%
2014	59.42 Million NOK	0.0%

Year	Operating Expenses	Operating Expenses Growth
2024 Q1	23.74 Million NOK	-45.92%
2024 Q2	51.76 Million NOK	118.03%
2023 Q3	28.09 Million NOK	-41.19%
2023 Q2	47.76 Million NOK	-34.05%
2023 FY	192.17 Million NOK	-37.2%
2023 Q1	72.42 Million NOK	-5.69%
2023 Q4	43.89 Million NOK	56.28%
2022 Q1	78.56 Million NOK	15.38%
2022 FY	306.02 Million NOK	-2.92%
2022 Q4	76.79 Million NOK	23.01%
2022 Q3	62.42 Million NOK	-29.25%
2022 Q2	88.23 Million NOK	12.31%
2021 Q2	92.3 Million NOK	10.65%
2021 Q3	71.41 Million NOK	-22.63%
2021 Q4	68.09 Million NOK	-4.66%
2021 Q1	83.41 Million NOK	15.18%
2021 FY	315.23 Million NOK	20.46%
2020 Q3	68.31 Million NOK	5.56%
2020 Q4	72.42 Million NOK	6.02%
2020 FY	261.69 Million NOK	22.7%
2020 Q1	56.23 Million NOK	-5.12%
2020 Q2	64.71 Million NOK	15.08%
2019 Q3	47.53 Million NOK	-8.52%
2019 FY	213.27 Million NOK	8.33%
2019 Q4	59.27 Million NOK	24.68%
2019 Q2	51.96 Million NOK	-4.65%
2019 Q1	54.49 Million NOK	2.36%
2018 Q3	38.11 Million NOK	-24.87%
2018 Q4	53.24 Million NOK	39.69%
2018 Q2	50.73 Million NOK	-7.39%
2018 FY	196.87 Million NOK	7.17%
2018 Q1	54.78 Million NOK	15.3%
2017 Q2	33.84 Million NOK	-48.56%
2017 Q1	65.78 Million NOK	134.68%
2017 FY	183.7 Million NOK	39.63%
2017 Q3	36.56 Million NOK	8.02%
2017 Q4	47.51 Million NOK	29.95%
2016 FY	131.57 Million NOK	80.42%
2016 Q3	16.34 Million NOK	-75.42%
2016 Q2	66.46 Million NOK	0.0%
2016 Q4	28.03 Million NOK	71.57%
2015 FY	72.92 Million NOK	22.72%
2014 FY	59.42 Million NOK	0.0%

Peer Operating Expenses Comparison of BerGenBio ASA

Name	Operating Expenses	Operating Expenses Difference
Arctic Bioscience AS	-5730.00 NOK	3353904.538%
Aqua Bio Technology ASA	18.46 Million NOK	-940.738%
ArcticZymes Technologies ASA	97.26 Million NOK	-97.573%
Hofseth BioCare ASA	156.04 Million NOK	-23.154%
PCI Biotech Holding ASA	25.23 Million NOK	-661.654%
Thor Medical ASA	7.16 Million NOK	-2583.606%
Ultimovacs ASA	215.73 Million NOK	10.922%